<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Wang J</submitter><funding>Science and Technology Commission of Shanghai Municipality</funding><funding>Shanghai Medical Discipline of Key Programs for General Surgery</funding><funding>Foundation of Shanghai Science and Technology Committee</funding><funding>National Natural Science Foundation of China</funding><funding>JianFeng Project of XuHui Provincial Commission of Health and Family Planning</funding><pagination>219-228</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC6942443</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>111(1)</volume><pubmed_abstract>Use of immune index is a new potential approach for cancer classification and prediction. To investigate the status and clinical effect of immune index in gallbladder cancer (GBC), 238 GBC patients from Zhongshan Hospital affiliated to Fudan University were involved in the present study, including 113 patients in a training set and 125 patients in a validation set. Five immune cells (macrophages, neutrophils, regulatory T cells, cytotoxic T cells and mast cells) were selected based on a literature review and the immune index for each patient was calculated using the LASSO regression. A low immune index (&lt;1) was defined as immunotype A and a high immune index (≥1) was defined as immunotype B. The 5-year overall survival rate for immunotype A was higher than that for immunotype B in the trai</pubmed_abstract><journal>Cancer science</journal><pubmed_title>Low immune index correlates with favorable prognosis but with reduced benefit from chemotherapy in gallbladder cancer.</pubmed_title><pmcid>PMC6942443</pmcid><funding_grant_id>16411952000</funding_grant_id><funding_grant_id>81600630</funding_grant_id><funding_grant_id>81872352</funding_grant_id><funding_grant_id>SHXH201703</funding_grant_id><funding_grant_id>2017ZZ02007</funding_grant_id><pubmed_authors>Liu H</pubmed_authors><pubmed_authors>Wang C</pubmed_authors><pubmed_authors>Chen L</pubmed_authors><pubmed_authors>Suo T</pubmed_authors><pubmed_authors>Wang J</pubmed_authors><pubmed_authors>Shi X</pubmed_authors><pubmed_authors>Li M</pubmed_authors><pubmed_authors>Ni X</pubmed_authors><pubmed_authors>Bo X</pubmed_authors><pubmed_authors>Shen S</pubmed_authors><pubmed_authors>Wang Y</pubmed_authors><pubmed_authors>Luo R</pubmed_authors><pubmed_authors>Lu P</pubmed_authors><pubmed_authors>Xin Y</pubmed_authors><pubmed_authors>Nan L</pubmed_authors></additional><is_claimable>false</is_claimable><name>Low immune index correlates with favorable prognosis but with reduced benefit from chemotherapy in gallbladder cancer.</name><description>Use of immune index is a new potential approach for cancer classification and prediction. To investigate the status and clinical effect of immune index in gallbladder cancer (GBC), 238 GBC patients from Zhongshan Hospital affiliated to Fudan University were involved in the present study, including 113 patients in a training set and 125 patients in a validation set. Five immune cells (macrophages, neutrophils, regulatory T cells, cytotoxic T cells and mast cells) were selected based on a literature review and the immune index for each patient was calculated using the LASSO regression. A low immune index (&lt;1) was defined as immunotype A and a high immune index (≥1) was defined as immunotype B. The 5-year overall survival rate for immunotype A was higher than that for immunotype B in the trai</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020 Jan</publication><modification>2025-04-19T08:54:44.102Z</modification><creation>2020-05-22T07:16:16Z</creation></dates><accession>S-EPMC6942443</accession><cross_references><pubmed>31729088</pubmed><doi>10.1111/cas.14239</doi></cross_references></HashMap>